Palavras-chave
Como Citar
Resumo
Epithelial ovarian cancer is a malignant neoplasm that represents the majority of ovarian cancer cases. It is characterized by aggressiveness, often late diagnosis and therapeutic challenges. Early diagnosis is crucial to improving patients' survival rates and quality of life. Individualized treatment, combining chemotherapy and targeted therapy, has been a promising approach to optimize therapeutic results and minimize adverse effects. Objective: to analyze and synthesize the available evidence on the importance of early diagnosis and individualized treatment with combined chemotherapy and targeted therapy in epithelial ovarian cancer. Methodology: Using the PRISMA checklist, this review was conducted based on articles published in the last 10 years. The databases used were: PubMed, Scielo, Web of Science. The descriptors: "epithelial ovarian cancer", "early diagnosis", "individualized treatment", "combined chemotherapy", "targeted therapy". Inclusion criteria: original studies in humans, published in English or Portuguese, addressing the early diagnosis and/or individualized treatment of epithelial ovarian cancer. Exclusion criteria: animal studies, systematic reviews, studies with non-representative samples. Results: The results of this review highlight the importance of early diagnosis through imaging techniques and tumor markers. Furthermore, they highlight the effectiveness of combination chemotherapy, especially regimens containing platinum and taxanes, together with targeted therapy, such as PARP inhibitors, in improving response rates and survival in patients with epithelial ovarian cancer. Conclusion: Early diagnosis and individualized treatment with combination chemotherapy and targeted therapy play a key role in the management of epithelial ovarian cancer. This multifaceted approach can significantly improve patients' clinical outcomes and quality of life, highlighting the importance of personalized therapeutic strategies in this challenging clinical context.
Referências
Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019 Mar 23;393(10177):1240-1253. doi: 10.1016/S0140-6736(18)32552-2.
Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020 Nov 9;371:m3773. doi: 10.1136/bmj.m3773.
Sambasivan S. Epithelial ovarian cancer: Review article. Cancer Treat Res Commun. 2022;33:100629. doi: 10.1016/j.ctarc.2022.100629.
Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019 Jul;69(4):280-304. doi: 10.3322/caac.21559.
Arnaoutoglou C, Dampala K, Anthoulakis C, Papanikolaou EG, Tentas I, Dragoutsos G, Machairiotis N, Zarogoulidis P, Ioannidis A, Matthaios D, Perdikouri EI, Giannakidis D, Sardeli C, Petousis S, Oikonomou P, Nikolaou C, Charalampidis C , Sapalidis K. Epithelial Ovarian Cancer: A Five Year Review. Medicine (Kaunas). 2023 Jun 21;59(7):1183. doi: 10.3390/medicina59071183.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Feb 2;19(2):191-226. doi: 10.6004/jnccn.2021.0007.
.Orr B, Edwards RP. Diagnosis and Treatment of Ovarian Cancer. Hematol Oncol Clin North Am. 2018 Dec;32(6):943-964. doi: 10.1016/j.hoc.2018.07.010.
Gupta S, Nag S, Aggarwal S, Rauthan A, Warrier N. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review. J Ovarian Res 2019 Nov 4;12(1):103. doi: 10.1186/s13048-019-0579-0.
Sellers TA, Peres LC, Hathaway CA, Tworoger SS. Prevention of Epithelial Ovarian Cancer. Cold Spring Harb Perspect Med 2023 Aug 1;13(8):a038216. doi: 10.1101/cshperspect.a038216.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020 Apr 10;38(11):1222-1245. doi: 10.1200/JCO.19.02960.
Shah S, Cheung A, Kutka M, Sheriff M, Boussios S. Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes. Int J Environ Res Public Health. 2022 Jul 1;19(13):8113. doi: 10.3390/ijerph19138113.
Amin N, Chaabouni N, George A. Genetic testing for epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2020 May;65:125-138. doi: 10.1016/j.bpobgyn.2020.01.005.
Pignata S, Pisano C, Di Napoli M, Cecere SC, Tambaro R, Attademo L. Treatment of recurrent epithelial ovarian cancer. Cancer. 2019 Dec 15;125 Suppl 24:4609-4615. doi: 10.1002/cncr.32500.
Bund V, Azaïs H, Bibi-Triki S, Lecointre L, Betrian SB, Angeles MA, Eberst L, Faller E, Boisramé T, Bendifallah S, Akladios C, Deluche É; SFOG Campus. Basics of immunotherapy for epithelial ovarian cancer. J Gynecol Obstet Hum Reprod. 2022 Feb;51(2):102283. doi: 10.1016/j.jogoh.2021.102283.
Elsherif S, Javadi S, Viswanathan C, Faria S, Bhosale P. Low-grade epithelial ovarian cancer: what a radiologist should know. Br J Radiol. 2019 Mar;92(1095):20180571. doi: 10.1259/bjr.20180571.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Ana Clara Rodrigues Franco, Maria Gabriella Cunha Batista, Eduardo Henrique Mendes Rezende, Murilo Dell Eugenio Costa Filho, Mayra Algeri Schimin, Durval José dos Santos Filho, Raylton Jansen e Silva Segundo, Lucas Torres de Araújo, Natana Carol Alves , Bruno Barbosa Pinheiro